Bruker vs Medpace Holdings
Bruker is the larger business, with $3.44bn of revenue in fiscal 2025 against $2.53bn for Medpace Holdings (1.4 times as much). Medpace Holdings grew faster (20.0% against 2.1%). Medpace Holdings kept more of each dollar of sales as profit: a net margin of 17.8% against -0.3%. Medpace Holdings carries less debt relative to equity (0.0% against 76.1%).
| Latest fiscal year | BrukerBRKR, 2025 | Medpace HoldingsMEDP, 2025 |
|---|---|---|
| Revenue | $3.44bn | $2.53bn |
| Revenue growth | 2.1% | 20.0% |
| Net income | −$8.6m | $451m |
| Operating margin | 2.0% | 21.1% |
| Net margin | -0.3% | 17.8% |
| Return on equity | -0.4% | 70.2% |
| Free cash flow | $43.3m | $682m |
| Cash | $299m | $497m |
| Total debt | $1.87bn | $0 |
| Debt to equity | 76.1% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | 0.3% | — |
| Share buybacks | $10.0m | $917m |
| Employees | 11,085 | 6,200 |
| Market value | $8.56bn | $18.66bn |
| Price vs our value range | Above our value range | Below our value range |
| Moat score | 66 (Moderate) | 89 (Strong) |
| Insider trades, 12 months | 0 buys, 16 sales | 0 buys, 56 sales |